These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide. Kastritis E; Dimopoulos M Leuk Lymphoma; 2007 Dec; 48(12):2295-7. PubMed ID: 18066998 [No Abstract] [Full Text] [Related]
27. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633 [TBL] [Abstract][Full Text] [Related]
28. Thalidomide-associated thrombocytopenia. Duyvendak M; Naunton M; Kingma BJ; Brouwers JR Ann Pharmacother; 2005 Nov; 39(11):1936-9. PubMed ID: 16219892 [TBL] [Abstract][Full Text] [Related]
29. [Evaluation of blood morphology in patients with refractory multiple myeloma treated with thalidomide]. Grzaśko N; Dmoszyńska A; Krawczyk S; Hus M; Soroka-Wojtaszko M; Ciepłuch H; Hellmann A Pol Arch Med Wewn; 2001 Jul; 106(1):573-9. PubMed ID: 11928568 [TBL] [Abstract][Full Text] [Related]
30. Lenalidomide in myelodysplastic syndrome and multiple myeloma. Shah SR; Tran TM Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955 [TBL] [Abstract][Full Text] [Related]
31. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Poser M; Müller S; Flasshove M; Moritz T; Seeber S; Nowrousian MR Ann Hematol; 2005 Sep; 84(9):594-600. PubMed ID: 15744524 [TBL] [Abstract][Full Text] [Related]
32. [Desirable and undesirable effects of thalidomide in patients with multiple myeloma]. Foldyna D; Kamelander J; Krejcí M; Hájek R Vnitr Lek; 2003 Nov; 49(11):859-68. PubMed ID: 14689682 [TBL] [Abstract][Full Text] [Related]
33. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P Eur J Haematol; 2004 Jun; 72(6):403-9. PubMed ID: 15128418 [TBL] [Abstract][Full Text] [Related]
34. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676 [TBL] [Abstract][Full Text] [Related]
35. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799 [TBL] [Abstract][Full Text] [Related]
36. Thalidomide dosing in patients with relapsed or refractory multiple myeloma. Thompson JL; Hansen LA Ann Pharmacother; 2003 Apr; 37(4):571-6. PubMed ID: 12659617 [TBL] [Abstract][Full Text] [Related]
37. [Single-agent thalidomide for advanced and refractory multiple myeloma]. Okikawa Y; Takimoto Y; Noda M; Imagawa J; Katayama Y; Sakai A; Okita H; Fujimura K; Kimura A Rinsho Ketsueki; 2003 Jun; 44(6):368-74. PubMed ID: 12884814 [TBL] [Abstract][Full Text] [Related]
38. Thalidomide in relapsed or refractory multiple myeloma: how much and for how long? Abdalla SH; Mahmoud S Leuk Lymphoma; 2003 Jun; 44(6):989-91. PubMed ID: 12854899 [TBL] [Abstract][Full Text] [Related]
39. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group]. Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K; Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523 [TBL] [Abstract][Full Text] [Related]
40. A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. Kodama T; Abe M; Iida S; Ozaki S; Sakai A; Sawamura M; Shimazaki C; Miyata A; Wakayama T; Murakami H Clin Lymphoma Myeloma; 2009 Apr; 9(2):154-9. PubMed ID: 19406727 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]